These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 15913990)

  • 1. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma.
    Scotlandi K; Manara MC; Hattinger CM; Benini S; Perdichizzi S; Pasello M; Bacci G; Zanella L; Bertoni F; Picci P; Serra M
    Eur J Cancer; 2005 Jun; 41(9):1349-61. PubMed ID: 15913990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
    Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
    Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
    Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ
    J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma.
    Thomas DG; Giordano TJ; Sanders D; Biermann JS; Baker L
    Clin Cancer Res; 2002 Mar; 8(3):788-93. PubMed ID: 11895910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma.
    Pahl JH; Ruslan SE; Buddingh EP; Santos SJ; Szuhai K; Serra M; Gelderblom H; Hogendoorn PC; Egeler RM; Schilham MW; Lankester AC
    Clin Cancer Res; 2012 Jan; 18(2):432-41. PubMed ID: 22090361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
    Scotlandi K; Perdichizzi S; Manara MC; Serra M; Benini S; Cerisano V; Strammiello R; Mercuri M; Reverter-Branchat G; Faircloth G; D'Incalci M; Picci P
    Clin Cancer Res; 2002 Dec; 8(12):3893-903. PubMed ID: 12473605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71.
    Manara MC; Perdichizzi S; Serra M; Pierini R; Benini S; Hattinger CM; Astolfi A; Bagnati R; D'Incalci M; Picci P; Scotlandi K
    Int J Oncol; 2005 Dec; 27(6):1605-16. PubMed ID: 16273217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells.
    Benini S; Manara MC; Baldini N; Cerisano V; Massimo Serra ; Mercuri M; Lollini PL; Nanni P; Picci P; Scotlandi K
    Clin Cancer Res; 2001 Jun; 7(6):1790-7. PubMed ID: 11410521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and therapeutic relevance of the IGF pathway in Ewing's sarcoma patients.
    van de Luijtgaarden AC; Versleijen-Jonkers YM; Roeffen MH; Schreuder HW; Flucke UE; van der Graaf WT
    Target Oncol; 2013 Dec; 8(4):253-60. PubMed ID: 23292309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas.
    Anninga JK; van de Vijver MJ; Cleton-Jansen AM; Kristel PM; Taminiau AH; Nooij M; Egeler RM; Hogendoorn PC
    Eur J Cancer; 2004 May; 40(7):963-70. PubMed ID: 15093570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The epidermal growth factor receptor HER2 is not a major therapeutic target in Ewing sarcoma.
    Ye D; Maitra A; Timmons CF; Leavey PJ; Ashfaq R; Ilaria RL
    J Pediatr Hematol Oncol; 2003 Jun; 25(6):459-66. PubMed ID: 12794524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions.
    Scotlandi K; Manara MC; Strammiello R; Landuzzi L; Benini S; Perdichizzi S; Serra M; Astolfi A; Nicoletti G; Lollini PL; Bertoni F; Nanni P; Picci P
    J Clin Oncol; 2003 May; 21(10):1952-60. PubMed ID: 12743148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study.
    Somers GR; Ho M; Zielenska M; Squire JA; Thorner PS
    Pediatr Dev Pathol; 2005; 8(5):525-32. PubMed ID: 16211448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.
    Tap WD; Demetri G; Barnette P; Desai J; Kavan P; Tozer R; Benedetto PW; Friberg G; Deng H; McCaffery I; Leitch I; Badola S; Chang S; Zhu M; Tolcher A
    J Clin Oncol; 2012 May; 30(15):1849-56. PubMed ID: 22508822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives.
    Fleuren ED; Versleijen-Jonkers YM; Boerman OC; van der Graaf WT
    Biochim Biophys Acta; 2014 Apr; 1845(2):266-76. PubMed ID: 24582852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell surface receptor expression patterns in osteosarcoma.
    Hassan SE; Bekarev M; Kim MY; Lin J; Piperdi S; Gorlick R; Geller DS
    Cancer; 2012 Feb; 118(3):740-9. PubMed ID: 21751203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group.
    Schwartz CL; Gorlick R; Teot L; Krailo M; Chen Z; Goorin A; Grier HE; Bernstein ML; Meyers P;
    J Clin Oncol; 2007 May; 25(15):2057-62. PubMed ID: 17513810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
    Bennani-Baiti IM; Machado I; Llombart-Bosch A; Kovar H
    Hum Pathol; 2012 Aug; 43(8):1300-7. PubMed ID: 22245111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy.
    Nakatani F; Ferracin M; Manara MC; Ventura S; Del Monaco V; Ferrari S; Alberghini M; Grilli A; Knuutila S; Schaefer KL; Mattia G; Negrini M; Picci P; Serra M; Scotlandi K
    J Pathol; 2012 Apr; 226(5):796-805. PubMed ID: 21960059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.